NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
NOVAVAX INC (NVAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $40.37 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2021-03-01
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2018-03-31 was $4.99.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2016-03-31 was $8.72.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2015-03-31 was $0.00.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2020 was $40.37, a 320.08% increase from fiscal 2019.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2019 was $9.61.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2016 was $8.72.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2020-12-31 | $40.37 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $9.61 10-K · filed 2020-03-11 | |||
| 2018-09-30 | $4.99 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $4.99 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $4.99 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $8.72 10-K · filed 2017-02-27 | |||
| 2016-09-30 | $8.72 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $8.72 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $8.72 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |